DUSP28 and pancreatic neoplasm: Drugs currently used in clinical trials – gemcitabine and doxorubicin – were tested in a dose-dependent manner (0, 1, 10, 100, 1000 nM) to treat seven different human pancreatic cancer cells to assess the role of DUSP28 in drug resistance.